Stem Cell Therapy for CLI

About ProVascTec

ProVascTec is an Irish preclinical biotech targeting critical limb ischemia (CLI) with a novel cell therapy approach. The company's technology aims to induce neovascularization via stem cell paracrine signaling, delivered via a proprietary device to create a 'natural bypass' around blocked arteries below the knee. Embedded within Europe's largest healthtech venture builder, NLC, the company is led by an experienced pharmaceutical manager and a serial inventor. Its strategy focuses on addressing a significant unmet medical need in peripheral artery disease where current interventions often fail.

Therapeutic Areas